Medicare coverage will cut obesity-drug prices but open the door to millions of new patients.

The Trump administration plans to announce a deal with pharmaceutical companies to sell discounted weight-loss drugs through TrumpRx, a government-run platform.

Access to the drugs has been a consistent problem for patients because of their cost — around $500 a month for higher doses — and insurance coverage has been spotty.

Trump’s GLP-1 price deal slashes costs and expands selective Medicare coverage—threatening telehealth startups and sparking a longevity-driven reset.

The Trump administration is reportedly finalizing a deal with Eli Lilly and Novo Nordisk that would lower prices on Wegovy, Zepbound and possibly Ozempic.

According to Reuters, Lilly could offer the lowest dose of its popular weight loss drug Zepbound at $149 a month, and Novo’s Wegovy could be offered at $299 a month through TrumpRx. In return, the two drugs could also gain coverage under Medicare.

President Trump’s strategy to lower prescription drug prices will be put to the test as drugmakers must now commit to the terms of his “Most Favored Nation” pricing plan or face unspecified actions from the federal government. Trump gave drugmakers ...